Compare CSPI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSPI | RFL |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.6M | 92.6M |
| IPO Year | 1994 | 2017 |
| Metric | CSPI | RFL |
|---|---|---|
| Price | $8.49 | $2.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.6K | ★ 274.0K |
| Earning Date | 05-08-2026 | 06-10-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 75.00 | 28.28 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $58,730,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $219.00 | ★ N/A |
| Revenue Growth | 6.36 | ★ 43.96 |
| 52 Week Low | $7.55 | $1.12 |
| 52 Week High | $15.00 | $2.95 |
| Indicator | CSPI | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 73.51 |
| Support Level | $7.98 | $1.22 |
| Resistance Level | $9.31 | N/A |
| Average True Range (ATR) | 0.69 | 0.32 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 19.14 | 81.75 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.